NP_076087.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
31,400 Da
NCBI Official Full Name
AT-rich interactive domain-containing protein 5B
NCBI Official Synonym Full Names
AT rich interactive domain 5B (MRF1-like)
NCBI Official Synonym Symbols
Mrf2; Desrt; AI467247; Mrf2beta; Mrf2alpha; 4930580B11; 5430435G07Rik [Similar Products]
NCBI Protein Information
AT-rich interactive domain-containing protein 5B; MRF-2; ARID class DNA binding protein; modulator recognition factor 2; ARID domain-containing protein 5B; modulator recognition factor protein 2; AT rich interactive domain 5B (Mrf1 like); developmentally and sexually retarded with transient immune abnormalities protein
UniProt Protein Name
AT-rich interactive domain-containing protein 5B
UniProt Synonym Protein Names
Developmentally and sexually retarded with transient immune abnormalities protein; Desrt; MRF1-like; Modulator recognition factor protein 2; MRF-2
UniProt Synonym Gene Names
UniProt Entry Name
ARI5B_MOUSE
UniProt Comments for ARID5B
Mrf-2: Transcription coactivator that binds to the 5'-AATA[CT]- 3' core sequence and plays a key role in adipogenesis and liver development. Acts by forming a complex with phosphorylated PHF2, which mediates demethylation at Lys-336, leading to target the PHF2-ARID5B complex to target promoters, where PHF2 mediates demethylation of dimethylated 'Lys-9' of histone H3 (H3K9me2), followed by transcription activation of target genes. The PHF2- ARID5B complex acts as a coactivator of HNF4A in liver. Required for adipogenesis: regulates triglyceride metabolism in adipocytes by regulating expression of adipogenic genes. Overexpression leads to induction of smooth muscle marker genes, suggesting that it may also act as a regulator of smooth muscle cell differentiation and proliferation. Represses the cytomegalovirus enhancer. Defects in ARID5B may be a cause of susceptibility to coronary atherosclerosis in the Japanese population. Defects in ARID5B may be a cause of susceptibility to acute lymphoblastic leukemia (ALL). ALL is a subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphonodes. Belongs to the ARID5B family. 3 isoforms of the human protein are produced by alternative splicing.
Cellular Component: nucleus
Molecular Function: DNA binding; transcription coactivator activity
Biological Process: fat cell differentiation; transcription from RNA polymerase II promoter; transcription, DNA-dependent; adrenal gland development; multicellular organism growth; male gonad development; platelet-derived growth factor receptor signaling pathway; palate development; negative regulation of transcription from RNA polymerase II promoter; post-embryonic development; regulation of transcription from RNA polymerase II promoter; nitrogen compound metabolic process; regulation of transcription, DNA-dependent; skeletal morphogenesis; positive regulation of transcription factor activity; kidney development; cell development; muscle morphogenesis; female gonad development
Research Articles on ARID5B
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with ARID5B elisa kit
Diseases associated with ARID5B elisa kit
Organs/Tissues associated with ARID5B elisa kit
|